HPCwire: Supercomputer Points Researchers to New Blood Pressure Drug

Since 1986 - Covering the Fastest Computers
in the World and the People Who Run Them

Translation Disclaimer

Subscribe | Sign In

Visit additional Tabor Communication Publications

Leading HPC
Solution Providers

May 01, 2008

Supercomputer Points Researchers to New Blood Pressure Drug

GAINESVILLE, Fla., May 1 -- University of Florida researchers have identified a drug compound that dramatically lowers blood pressure, improves heart function and -- in a remarkable finding -- prevents damage to the heart and kidneys in rats with persistent hypertension.

The findings, which appear in today’s (May 1) edition of the American Heart Association journal Hypertension, could lead to a new class of antihypertensive drugs designed to address two major problems associated with cardiovascular disease: high blood pressure and the tissue damage associated with it, known as fibrosis.

“When people have heart attacks (or suffer from hypertension) the blood vessels get more rigid,” said study author David Ostrov, an assistant professor in the UF College of Medicine’s department of pathology, immunology and laboratory medicine. “We discovered a compound that reverses the fibrosis that makes the blood vessels more rigid.”

The American Heart Association estimates that 72 million people in the United States have high blood pressure, a major risk factor for stroke, heart attack and death.

Angiotensin-converting enzyme plays a key role in the development of high blood pressure. It produces angiotensin II, a potent hormone that triggers the condition and contributes to the development of cardiovascular disease by constricting blood vessels, causing blood pressure to rise. That’s why millions of Americans with hypertension and cardiovascular disease take ACE inhibitors. But these drugs have limited capacity to repair heart function and to reverse tissue damage.

In contrast, the enzyme ACE2 not only lowers levels of angiotensin II but also converts it to a hormone that helps protect the cardiovascular system.

“Only recently has it come to be appreciated that ACE and ACE2 play a very important role in balancing the activity of the other one to maintain normal blood pressure,” Ostrov said. “They work in harmony.”

Hypothesizing that activating ACE2 could be beneficial, UF scientists set out to discover a compound that enhances the enzyme’s activity.

Researchers used one of the world’s most powerful supercomputers to process 140,000 prospective drug compounds in a matter of weeks. The computer predicted which molecules would be most likely to enhance the activity of ACE2, rotating them in thousands of different orientations to see how they would bind to certain pockets on the enzyme’s surface.

“This project had a very small likelihood of succeeding because it’s much easier to inhibit activity rather than to enhance it. By analogy, it’s easier to break something than to build it,” Ostrov said. “If you consider the structure of an enzyme’s active site it’s easy to see that if you plug up the active site it’s not going to work. But how can one make the enzyme actually work better? This seemed to be a very significant challenge we were probably not likely to overcome. We tried anyway.”

And it worked.

“That in itself is a significant accomplishment because no one has ever specifically identified a compound that enhances the activity of an enzyme using a rational structure-based approach,” he said. “In other words, no one has ever done this before on purpose. People have discovered molecules that enhance the activity of enzymes by trial and error, but no group has ever done it in a specifically pointed way like this.”

Ostrov said the enzyme exists in two forms: like a Pac-Man with a mouth that has chomped closed, and like a Pac-Man with a mouth that remains wide open. The molecule that worked best fit in a structural pocket in the enzyme’s open conformation.

“So in other words, stabilizing the open conformation may be the reason why we enhance the activity of the enzyme,” he said

After hitting on the “lead” compound, UF researchers then tested it in hypertensive rats that had developed fibrosis of the heart and kidney. The animals received the drug for two weeks. Tissue samples from treated animals revealed a significant decrease in fibrosis of the heart, kidney and blood vessels, said Ostrov, who described the findings as “striking and reproducible.”

The study was funded by grants from the National Institutes of Health and the American Heart Association and was a collaborative effort of the UF colleges of Medicine, Pharmacy and Liberal Arts and Sciences. Researchers also included Mohan Raizada, a distinguished professor of physiology and functional genomics, Michael J. Katovich, a professor of pharmacodynamics, and Ronald K. Castellano, an assistant professor of chemistry, among others.

Early results also show the compound inhibits inflammation, which has significant implications for a number of human diseases, including autoimmune diseases such as type 1 diabetes and rheumatoid arthritis as well as other diseases involving fibrosis, such as Alzheimer’s, Ostrov said.

Additional research will continue to explore the compound’s effectiveness in animals and humans.

-----

Source: University of Florida

Share Options

Subscribe

Subscribe to HPCwire

Discussion

There are 0 discussion items posted.

Join the Discussion

Become a Registered User Today!

Registered Users Log in join the Discussion

RSS Feeds

Feeds by Topic

Feeds by Industry

Feeds by Content Type

Subscribe to All Content

All

May 23, 2012

May 22, 2012

May 21, 2012

May 18, 2012

May 17, 2012

May 16, 2012

May 15, 2012

May 14, 2012

May 11, 2012

Feature Articles

NVIDIA Works On CPU Co-Dependency Issues with Kepler GPU

NVIDIA is telling everyone that the GK110, its new Kepler GPU aimed at supercomputing, is all about improving performance per watt. But the other driving theme behind the new architecture is reducing the GPU's reliance on its CPU host. How well it accomplishes both these goals areas could determine the success of the new chip in high performance computing.
Read more...

OpenACC Starts to Gather Developer Mindshare

PGI, Cray, and CAPS enterprise are moving quickly to get their new OpenACC-supported compilers into the hands of GPGPU developers. At NVIDIA's GPU Technology Conference this week, there was plenty of discussion around the new HPC accelerator framework, and all three OpenACC compiler makers, as well as NVIDIA, were talking up the technology.
Read more...

NVIDIA Launches Kepler Into HPC

NVIDIA has introduced its first Kepler-generation GPU product for high performance computing, and revealed some of the inner working of the new architecture. The announcement took place at the kickoff of the company's GPU Technology Conference taking place this week in San Jose, California.
Read more...